Rockland, Massachusetts, December 6, 2007 - EMD Serono, Inc. announced today the availability of easypod, the first of its kind automated device in the growth hormone therapeutic area. easypod was developed for the administration of Saizen [somatropin (rDNA origin) for injection], the companys treatment for growth hormone deficiency. A 2007 Gold Medal recipient of the Medical Design Excellence Awards, easypod was designed in conjunction with patients, caregivers and healthcare professionals to answer the need for a device that provided simple everyday use while monitoring patient adherence. On October 31, 2007, easypod received approval from the US Food and Drug Administration (FDA) and is now available to patients through their healthcare providers.
As a physician who treats children with growth hormone deficiency, I am encouraged by the new technology in easypod, said Henry Anhalt, D.O., FAAP, FACOP, FACE, CDE, Director of the Division of Pediatric Endocrinology and Diabetes at Saint Barnabas Medical Center. It is the first growth hormone delivery device that allows healthcare professionals to preset their patients daily dose in advance and then monitor their compliance to the treatment schedule.
Over seven hundred patients, caregivers and healthcare professionals were surveyed for input on how to improve upon delivery systems for growth hormone therapy during the development phase of easypod. One of the key features of easypod is preset dosing, which means patients no longer have to set their dose each day. Another unique feature is the dose confirmation screen that notifies patients when they have properly administered their treatment. easypod also logs the date and dose of each injection, allowing healthcare professionals to monitor patient adherence.
We are proud to bring products like easypod to market that utilize breakthrough technology to provide patients and healthcare professionals with devices that are simple to use
|Contact: Michele Baer|